Nesfrotamig

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A humanized immunoglobulin G1 (IgG1) bispecific antibody targeting both the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2) and the costimulatory receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, nesfrotamig simultaneously targets and binds to HER2 expressed on tumor cells and 4-1BB expressed on activated T-lymphocytes and natural killer (NK) cells. This crosslinks HER2-expressing tumor cells and 4-1BB-expressing T-cells and NK cells, and activates 4-1BB signaling locally in the tumor microenvironment (TME). This results in cytotoxic T-cell co-stimulation and enhances T-lymphocyte-mediated anti-tumor activity. Nesfrotamig also promotes the secretion of interferon-gamma (IFNg) from T-cells, which leads to tumor cell lysis. In addition, the binding of nesfrotamig to HER2 prevents HER2-mediated signaling. This inhibits the proliferation of HER2-expressing tumor cells. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.

**Synonyms:** - ABL 105 - ABL-105 - ABL105 - Anti-HER2/4-1BB Bispecific Antibody ABL105 - Anti-HER2/4-1BB Bispecific Antibody YH32367 - Anti-HER2/Anti-4-1BB Bispecific Antibody YH32367 - HER2 x 4-1BB Bispecific Antibody YH32367 - NESFROTAMIG - YH 32367 - YH-32367 - YH32367